The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Athira Pharma Inc shares valued at $66,179 were purchased by Romano Kelly A on Jun 24 ’24. At $2.42 per share, Romano Kelly A acquired 27,400 shares. The insider’s holdings grew to 80,715 shares worth approximately $49236.15 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Romano Kelly A purchased 15,000 shares, netting a total of over 33,872 in proceeds. Following the buying of shares at $2.26 each, the insider now holds 53,315 shares.
Before that, Litton Mark James had sold 4,820 shares from its account. In a trade valued at $14,026, the Chief Executive Officer traded Athira Pharma Inc shares for $2.91 each. Upon closing the transaction, the insider’s holdings decreased to 4,820 shares, worth approximately $88082.17.
As published in a research note from Rodman & Renshaw on September 04, 2024, Athira Pharma Inc [ATHA] has been rated down from a Buy to a Neutral. Analysts at JMP Securities downgraded the stock from ‘”a Mkt outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in early September. As of September 04, 2024, BTIG Research has decreased its “Buy” rating to a “Neutral” for ATHA. Earlier on August 19, 2024, Rodman & Renshaw initiated its rating. Their recommendation was “a Buy” for ATHA stock.
Analyzing ATHA Stock Performance
During the last five days, there has been a drop of approximately -81.50%. Over the course of the year, Athira Pharma Inc shares have dropped approximately -74.88%. Shares of the company reached a 52-week high of $4.30 on 02/21/24 and a 52-week low of $0.60 on 09/04/24. A 50-day SMA is recorded $3.03, while a 200-day SMA reached $2.70. Nevertheless, trading volume fell to 17.48 million shares from 3.32 million shares the previous day.
Support And Resistance Levels for Athira Pharma Inc (ATHA)
According to the 24-hour chart, there is a support level at 0.57, which, if violated, would cause prices to drop to 0.53. In the upper region, resistance lies at 0.68. The next price resistance is at 0.75. RSI (Relative Strength Index) is 15.75 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.81, which suggests the price will decrease in the coming days. Percent R is at 99.64%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
